Cure SMA is excited to share that we will be continuing the Summit of Strength Program in 2021, offering a hybrid of the original in-person events and the webinars launched in 2020. This ...
There are plenty of reasons for everyone to exercise regularly, but for the spinal muscular atrophy (SMA) community, exercise has potential benefits in supporting greater muscle strength and motor function. With many still ...
You can get a head start on your healthy New Year’s resolutions and sign up today for our 2021 Team Cure SMA endurance race series! Team Cure SMA is an endurance program that ...
With consideration of the current COVID-19 pandemic and beyond, Cure SMA continues to advocate for the importance of overall health and wellness. Therefore, we are pleased to announce we will be hosting a ...
Recently, Cure SMA and colleagues at Novartis Gene Therapies published a manuscript titled, “Economic burden of spinal muscular atrophy: an analysis of claims data” in the Journal of Market Access & Health Policy. ...
As we continue to quarantine and see a new wave of COVID-19 cases across the country, Cure SMA would like you to know that our work for the spinal muscular atrophy (SMA) community ...
Each year since 2017, Cure SMA has conducted a Community Update Survey. This online questionnaire is sent to all individuals with spinal muscular atrophy (SMA) and caregivers of children with SMA in the ...
A little more than six months ago, Cure SMA launched the Summit of Strength Virtual Webinar Series , a program designed to help support individuals and families with SMA manage the uncertainty of ...
Through Cure SMA’s partnership with NeurologyLive, a new patient-centered article, “Early Intervention in SMA: How Access to Therapy Will Alter Disease Management As We Know It,” is now available for viewing ...
Cure SMA has published a paper, titled “Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers,” in partnership with NeurologyLive. The article highlights findings from a recent survey conducted by ...
Novartis Gene Therapies today announced new interim data from the ongoing Phase 3 STR1VE-EU clinical trial for Zolgensma® (onasemnogene abeparvovec). The data demonstrates that patients with spinal muscular atrophy (SMA) Type ...
Team Biogen hit the ground running throughout the month of August in honor of SMA Awareness Month. Together, the team logged 22,059 miles collectively from August 1st to August ...
